• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Future Considerations for Friedreich Ataxia

Opinion
Video

Sub Subramony, M.D., discusses strategies to enhance support for patients with Friedreich ataxia in clinical settings and the broader community, along with his aspirations for future research aimed at addressing unmet needs in treatment and patient support.

Video content above is prompted by the following:

  1. How do you think we can enhance our support for patients with Friedreich ataxia both within clinical settings and within the broader community?
  2. What are your aspirations regarding future research and how these interventions address the unmet needs for treating and supporting patients with Friedreich ataxia?
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Pain May Be Indicator of MS Prior to Disease Onset: Study

January 6th 2025
Article

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.

Read More

Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com

Meta-Analysis: Vascular Function Worse in People With MS

January 3rd 2025
Article

The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.

Read More

lab test tubes | Image credit: kwanchaift – stock.adobe.com

Study Highlights Trends, Emerging Innovations in DMD Research

December 22nd 2024
Article

An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.

Read More

Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

October 9th 2024
Article

A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).

Read More

Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

September 26th 2024
Article

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Read More

The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

September 3rd 2024
Article

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.